论文信息 - Epstein–Barr virus neutralizing antibody levels and risk of multiple sclerosis

Epstein–Barr virus neutralizing antibody levels and risk of multiple sclerosis

Previous infection with Epstein–Barr virus (EBV) and infectious mononucleosis are established multiple sclerosis (MS) risk factors, and elevated serum titers of anti-EBV nuclear antigen (anti-EBNA) antibodies in healthy adults are strongly correlated with future MS risk. In this prospective study, we investigated the association between EBV neutralizing antibodies and MS risk. MS risk tended to be higher in individuals with high titers of neutralizing antibodies compared to those with low titers (relative risk [RR] = 2.2, 95% confidence interval [CI] 0.97–5.1). This association was attenuated after adjustment for anti-EBNA1 IgG Ab titers (RR = 1.4, 95% CI 0.5–3.5). This preliminary finding warrants further study in a larger population.

[1] J. W. Lindsey,et al. Epstein–Barr virus neutralizing and early antigen antibodies in multiple sclerosis , 2010, European journal of neurology.

[2] A. Ascherio,et al. Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis , 2010, Annals of neurology.

[3] A. Ascherio,et al. Epstein–Barr Virus Infection and Multiple Sclerosis: A Review , 2010, Journal of Neuroimmune Pharmacology.

[4] M. Moutschen,et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. , 2007, The Journal of infectious diseases.

[5] A. Ascherio,et al. Environmental risk factors for multiple sclerosis. Part I: The role of infection , 2007, Annals of neurology.

[6] D Spiegelman,et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. , 2001, JAMA.

[7] A. D. Wilson,et al. Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. , 1998, Journal of virological methods.

[8] G. Nemerow,et al. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d , 1987, Journal of virology.